Press Releases

WINTER PARK, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”) announced today that Philip R. Mays has been appointed Senior Vice President, Chief Financial Officer and Treasurer of the Company, effective as of June 17, 2024.

Mr. Mays was most recently the Chief Financial Officer of Shadowbox Studios, from September 2021 to February 2024. Prior to that, from June 2011 to September 2021, Mr. Mays served as... (continue reading...)

Meeting reconvenes on June 24, 2024, at 9:00 a.m. Cayman Islands time (10:00 a.m. Eastern Daylight Time)

All shareholders of record at the close of business on March 28, 2024 are encouraged to vote “FOR ALL” directors

GEORGE TOWN, Cayman Islands, May 31, 2024 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water supply and treatment plants, announced today that its 2024... (continue reading...)

WINTER PARK, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company” or “PINE”) announced today that Philip R. Mays has been appointed Senior Vice President, Chief Financial Officer and Treasurer of the Company, effective as of June 17, 2024.

Mr. Mays was most recently the Chief Financial Officer of Shadowbox Studios, from September 2021 to February 2024. Prior to that, from June 2011 to September 2021, Mr. Mays... (continue reading...)

WHEATON, Ill.--(BUSINESS WIRE)-- First Trust Advisors L.P. ("FTA") announces the declaration of the Monthly distribution for certain exchange-traded funds advised by FTA.

The following dates apply to today's distribution declaration:

Expected Ex-Dividend Date:

June 3, 2024

Record Date:

June 3, 2024

Payable Date:

June 4, 2024

Ticker

Exchange

Fund Name

Frequency

Ordinary Income Per... (continue reading...)

– Late-breaking data from phase 3 KONFIDENT trial of sebetralstat published in NEJM and presented concurrently at the European Academy of Allergy and Clinical Immunology Congress 2024 –

– Interim data from KONFIDENT-S open-label trial show median time to treatment of 9 minutes and median time to beginning of symptom relief for laryngeal attacks 1.3 hours –

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: ... (continue reading...)